



NPCA

National Prostate Cancer Audit

NPCA, Clinical Effectiveness Unit
Royal College of Surgeons of England
38-43 Lincoln's Inn Fields
London WC2A 3PE

E: NPCA@rcseng.ac.uk
T: 020 7869 6602 [LinkedIn](#)
[@npca-natcan.bsky.social](#)

NPCA Newsletter, February 2026

Quality Improvement Intervention -

ensuring men with metastatic prostate cancer are receiving appropriate treatment

The NPCA launched its **first quality improvement (QI) intervention**, which aims to **ensure men** with metastatic hormone sensitive prostate cancer are **receiving systemic treatment intensification where appropriate**. This stems from the initial observation reported in our [State of the Nation Report 2025](#) that 66% of men under 75yrs (range 39-87% by sMDT) and 29% of men 75yrs and older (range 11-57%) who were diagnosed with metastatic prostate cancer were receiving systemic treatment intensification within 12 months of diagnosis.

The QI intervention started with a **formal outlier process** for this performance indicator, results of which can be found [here](#). In collaboration with BURST, we hosted a [webinar](#) on Thursday 23rd October 2025 exploring the evidence base for use of anti-cancer systemic therapy in metastatic prostate cancer. The event was recorded and is available to [watch again](#).

Improving Data Collection Quality for Systemic Anti-Cancer Therapy (SACT) in Prostate Cancer

BACKGROUND

- Recent findings from the NPCA show a lower than expected percentage of men diagnosed with mHSPC receiving SACT treatment intensification

Under 75 years: 66%
75 years and older: 29%

Reported rates of men diagnosed with metastatic disease receiving SACT treatment intensification between Jan-Dec 2022 in England*

AIMS:
To improve the completeness, accuracy, and timeliness of SACT data submission for men receiving SACT for prostate cancer within participating NHS organisations

OBJECTIVES

- Increase the proportion of SACT record completeness
- Reduce data submission errors
- Strengthen collaborations between data management teams

INTERVENTION

Data Quality Audit and Feedback
Continuous Improvement Framework
Quality Improvement Initiatives
Active Feedback

CLINICAL RELEVANCE

- Among men in England diagnosed with hormone-sensitive metastatic prostate cancer (mHSPC) in 2022, only 47% (2,670 of 5,679) received SACT treatment intensification within 12 months*

TIMELINE

- OCT 2025: State of the Nation 2025 Report published
- JAN 2026: Launch of Data Dashboard
- Q1 2026: QI Webinar "Improving Data Collection Quality for SACT in prostate cancer"
- Q2 2026: QI Webinar "The use of SACT in metastatic prostate cancer"
- 2027: Active feedback

*NPCA State of the Nation Report 2025

NPCA@rcseng.ac.uk
@NPCA_uk

View the results of individual NHS Trusts and Cancer Alliances using our interactive Data Dashboard

Logos: Royal College of Surgeons of England, NHS England, HQIP, NDRS, GIG NHS, NHS Digital, NatCAN

On Thursday 8th January 2026, results for this performance indicator were made available on our [data dashboard](#) and will be updated quarterly.

On **Thursday 19th March 2026**, we will host a **data quality webinar** looking at **optimal data collection and processing strategies** for the systemic anti-cancer therapy (SACT) dataset. **Event registration can be found [here](#)**.

This webinar is **primarily aimed at cancer and data managers but clinicians and allied healthcare professionals are welcome**. Two case studies will explore best practice in SACT data collection and highlight common challenges with the aim of ultimately improving SACT data quality and completeness.

The [data dashboard](#) will be updated on Thursday 9th April 2026 and include patients diagnosed from 1st October 2022 to 31st March 2024.

Audit and feedback to providers will be used and repeated assessments will track progress over time.

New paper publication

The NPCA's latest paper, led by clinical fellow Arjun Nathan, reports on the [characteristics and outcomes of men presenting with complications of metastatic prostate cancer](#).

Summary findings are that the **risk of presenting with metastatic prostate cancer and metastatic-related events (MREs) varies according to age, socioeconomic deprivation, and residential region**. These men have **poorer survival outcomes** than men diagnosed without MREs at diagnosis.

NPCA editorial

The NPCA has published an invited editorial in Clinical Oncology entitled ['Future Directions of the National Prostate Cancer Audit'](#).

Please read and share!



This email was sent to you by NPCA, part of the National Cancer Audit Collaborating Centre (NATCAN) based at the Royal College of Surgeons of England. To ensure continued receipt of our emails please add us to your address book or safe list. In accordance with the General Data Protection Regulation (GDPR), NATCAN is committed to protecting your privacy. If you wish to know more please access our privacy policy. If you no longer wish to receive any messages please unsubscribe. © RCS 2023, Registered Charity No. 212808